Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors
It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated f...
Gespeichert in:
Veröffentlicht in: | Journal of medicinal chemistry 2002-09, Vol.45 (19), p.4128-4139 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4139 |
---|---|
container_issue | 19 |
container_start_page | 4128 |
container_title | Journal of medicinal chemistry |
container_volume | 45 |
creator | Orús, Lara Pérez-Silanes, Silvia Oficialdegui, Ana-M Martínez-Esparza, Javier Del Castillo, Juan-C Mourelle, Marisa Langer, Thierry Guccione, Salvatore Donzella, Giuseppina Krovat, Eva M Poptodorov, Konstantin Lasheras, Berta Ballaz, Santiago Hervías, Isabel Tordera, Rosa Del Río, Joaquín Monge, Antonio |
description | It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (K i < 50 nM) and the 5-HT1A receptors (K i < 20 nM) were further explored for their ability to stimulate [35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h−j and 8j,l antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice. |
doi_str_mv | 10.1021/jm0111200 |
format | Article |
fullrecord | <record><control><sourceid>acs_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_13895141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>a477679878</sourcerecordid><originalsourceid>FETCH-LOGICAL-a251t-472f4885a3c3473ef4714af883880d169e3a55dfe416585ef0eb87b6ced91c0e3</originalsourceid><addsrcrecordid>eNpFUctuFDEQtCIiZUk45A984Whw-zHjPS6BZBGBIHa5gJDlzLSzXiaeke08lv_hP3EICpfukrpUXaUi5Bj4K-ACXm-vOQAIzvfIDLTgTBmunpEZ50Iw0Qh5QJ7nvOWcSxByRn6vdrFsMIdMXezpx3HA7mZwqaIehxCv6OjpJ7yjwBZpNzDJvivmKprChMn9CpEB2w0_6pzSOLmI9C2mcOtKuMVM70LZ0GW42tCF9yGGsqOu0PqQrjCNZYwh0nVyMU9jKpj-eqgEzZZrWNAv2OFUxpSPyL53Q8YX__Yh-Xr6bn2yZOcXZ-9PFufMCQ2FqVZ4ZYx2spOqlehVC8p5Y6QxvIdmjtJp3XtU0Gij0XO8NO1l02E_h46jPCQvH3Unlzs3-OqsC9lOKVzXzBakmWtQUHnskRdywfunu0s_bdPKVtv155XVH_Q3bk7P7Jv_uq7LdjvepFhTWOD2oTP71Jn8A6vOiD0</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors</title><source>ACS Publications</source><creator>Orús, Lara ; Pérez-Silanes, Silvia ; Oficialdegui, Ana-M ; Martínez-Esparza, Javier ; Del Castillo, Juan-C ; Mourelle, Marisa ; Langer, Thierry ; Guccione, Salvatore ; Donzella, Giuseppina ; Krovat, Eva M ; Poptodorov, Konstantin ; Lasheras, Berta ; Ballaz, Santiago ; Hervías, Isabel ; Tordera, Rosa ; Del Río, Joaquín ; Monge, Antonio</creator><creatorcontrib>Orús, Lara ; Pérez-Silanes, Silvia ; Oficialdegui, Ana-M ; Martínez-Esparza, Javier ; Del Castillo, Juan-C ; Mourelle, Marisa ; Langer, Thierry ; Guccione, Salvatore ; Donzella, Giuseppina ; Krovat, Eva M ; Poptodorov, Konstantin ; Lasheras, Berta ; Ballaz, Santiago ; Hervías, Isabel ; Tordera, Rosa ; Del Río, Joaquín ; Monge, Antonio</creatorcontrib><description>It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (K i < 50 nM) and the 5-HT1A receptors (K i < 20 nM) were further explored for their ability to stimulate [35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h−j and 8j,l antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm0111200</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Biological and medical sciences ; Medical sciences ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Pharmacology. Drug treatments ; Serotoninergic system</subject><ispartof>Journal of medicinal chemistry, 2002-09, Vol.45 (19), p.4128-4139</ispartof><rights>Copyright © 2002 American Chemical Society</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm0111200$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm0111200$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,777,781,27057,27905,27906,56719,56769</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13895141$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Orús, Lara</creatorcontrib><creatorcontrib>Pérez-Silanes, Silvia</creatorcontrib><creatorcontrib>Oficialdegui, Ana-M</creatorcontrib><creatorcontrib>Martínez-Esparza, Javier</creatorcontrib><creatorcontrib>Del Castillo, Juan-C</creatorcontrib><creatorcontrib>Mourelle, Marisa</creatorcontrib><creatorcontrib>Langer, Thierry</creatorcontrib><creatorcontrib>Guccione, Salvatore</creatorcontrib><creatorcontrib>Donzella, Giuseppina</creatorcontrib><creatorcontrib>Krovat, Eva M</creatorcontrib><creatorcontrib>Poptodorov, Konstantin</creatorcontrib><creatorcontrib>Lasheras, Berta</creatorcontrib><creatorcontrib>Ballaz, Santiago</creatorcontrib><creatorcontrib>Hervías, Isabel</creatorcontrib><creatorcontrib>Tordera, Rosa</creatorcontrib><creatorcontrib>Del Río, Joaquín</creatorcontrib><creatorcontrib>Monge, Antonio</creatorcontrib><title>Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (K i < 50 nM) and the 5-HT1A receptors (K i < 20 nM) were further explored for their ability to stimulate [35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h−j and 8j,l antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.</description><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Pharmacology. Drug treatments</subject><subject>Serotoninergic system</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpFUctuFDEQtCIiZUk45A984Whw-zHjPS6BZBGBIHa5gJDlzLSzXiaeke08lv_hP3EICpfukrpUXaUi5Bj4K-ACXm-vOQAIzvfIDLTgTBmunpEZ50Iw0Qh5QJ7nvOWcSxByRn6vdrFsMIdMXezpx3HA7mZwqaIehxCv6OjpJ7yjwBZpNzDJvivmKprChMn9CpEB2w0_6pzSOLmI9C2mcOtKuMVM70LZ0GW42tCF9yGGsqOu0PqQrjCNZYwh0nVyMU9jKpj-eqgEzZZrWNAv2OFUxpSPyL53Q8YX__Yh-Xr6bn2yZOcXZ-9PFufMCQ2FqVZ4ZYx2spOqlehVC8p5Y6QxvIdmjtJp3XtU0Gij0XO8NO1l02E_h46jPCQvH3Unlzs3-OqsC9lOKVzXzBakmWtQUHnskRdywfunu0s_bdPKVtv155XVH_Q3bk7P7Jv_uq7LdjvepFhTWOD2oTP71Jn8A6vOiD0</recordid><startdate>20020912</startdate><enddate>20020912</enddate><creator>Orús, Lara</creator><creator>Pérez-Silanes, Silvia</creator><creator>Oficialdegui, Ana-M</creator><creator>Martínez-Esparza, Javier</creator><creator>Del Castillo, Juan-C</creator><creator>Mourelle, Marisa</creator><creator>Langer, Thierry</creator><creator>Guccione, Salvatore</creator><creator>Donzella, Giuseppina</creator><creator>Krovat, Eva M</creator><creator>Poptodorov, Konstantin</creator><creator>Lasheras, Berta</creator><creator>Ballaz, Santiago</creator><creator>Hervías, Isabel</creator><creator>Tordera, Rosa</creator><creator>Del Río, Joaquín</creator><creator>Monge, Antonio</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope></search><sort><creationdate>20020912</creationdate><title>Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors</title><author>Orús, Lara ; Pérez-Silanes, Silvia ; Oficialdegui, Ana-M ; Martínez-Esparza, Javier ; Del Castillo, Juan-C ; Mourelle, Marisa ; Langer, Thierry ; Guccione, Salvatore ; Donzella, Giuseppina ; Krovat, Eva M ; Poptodorov, Konstantin ; Lasheras, Berta ; Ballaz, Santiago ; Hervías, Isabel ; Tordera, Rosa ; Del Río, Joaquín ; Monge, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a251t-472f4885a3c3473ef4714af883880d169e3a55dfe416585ef0eb87b6ced91c0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Pharmacology. Drug treatments</topic><topic>Serotoninergic system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orús, Lara</creatorcontrib><creatorcontrib>Pérez-Silanes, Silvia</creatorcontrib><creatorcontrib>Oficialdegui, Ana-M</creatorcontrib><creatorcontrib>Martínez-Esparza, Javier</creatorcontrib><creatorcontrib>Del Castillo, Juan-C</creatorcontrib><creatorcontrib>Mourelle, Marisa</creatorcontrib><creatorcontrib>Langer, Thierry</creatorcontrib><creatorcontrib>Guccione, Salvatore</creatorcontrib><creatorcontrib>Donzella, Giuseppina</creatorcontrib><creatorcontrib>Krovat, Eva M</creatorcontrib><creatorcontrib>Poptodorov, Konstantin</creatorcontrib><creatorcontrib>Lasheras, Berta</creatorcontrib><creatorcontrib>Ballaz, Santiago</creatorcontrib><creatorcontrib>Hervías, Isabel</creatorcontrib><creatorcontrib>Tordera, Rosa</creatorcontrib><creatorcontrib>Del Río, Joaquín</creatorcontrib><creatorcontrib>Monge, Antonio</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orús, Lara</au><au>Pérez-Silanes, Silvia</au><au>Oficialdegui, Ana-M</au><au>Martínez-Esparza, Javier</au><au>Del Castillo, Juan-C</au><au>Mourelle, Marisa</au><au>Langer, Thierry</au><au>Guccione, Salvatore</au><au>Donzella, Giuseppina</au><au>Krovat, Eva M</au><au>Poptodorov, Konstantin</au><au>Lasheras, Berta</au><au>Ballaz, Santiago</au><au>Hervías, Isabel</au><au>Tordera, Rosa</au><au>Del Río, Joaquín</au><au>Monge, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2002-09-12</date><risdate>2002</risdate><volume>45</volume><issue>19</issue><spage>4128</spage><epage>4139</epage><pages>4128-4139</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (K i < 50 nM) and the 5-HT1A receptors (K i < 20 nM) were further explored for their ability to stimulate [35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h−j and 8j,l antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><doi>10.1021/jm0111200</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 2002-09, Vol.45 (19), p.4128-4139 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_pascalfrancis_primary_13895141 |
source | ACS Publications |
subjects | Biological and medical sciences Medical sciences Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Pharmacology. Drug treatments Serotoninergic system |
title | Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T02%3A22%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20Molecular%20Modeling%20of%20New%201-Aryl-3-%5B4-arylpiperazin-1-yl%5D-1-propane%20Derivatives%20with%20High%20Affinity%20at%20the%20Serotonin%20Transporter%20and%20at%205-HT1A%20Receptors&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Or%C3%BAs,%20Lara&rft.date=2002-09-12&rft.volume=45&rft.issue=19&rft.spage=4128&rft.epage=4139&rft.pages=4128-4139&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm0111200&rft_dat=%3Cacs_pasca%3Ea477679878%3C/acs_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |